Optometrist · Middletown, CT
NPI
1053663112
Since 2012
Specialty
Optometrist
Code 152W00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
400 Saybrook Rd
Middletown, CT, 06457
Phone (860) 347-7466
Groups this clinician bills Medicare through
Medicare paid, 2024
$62K
1,075 services
Medicare patients, 2024
409
Average age 74
Drug cost, 2024
$234K
972 prescriptions
Company payments, 2025
$612
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tamscot Yap was code 92014 (ophthalmological e&m), 303 times for 257 patients. In total Tamscot Yap billed 1,075 services in 21 codes, and Medicare paid $62K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-01-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92014 Ophthalmological E&M | Office | 303 | 257 | $85.65 | $26K |
| 92250 Angiography | Office | 190 | 173 | $26.69 | $5,071 |
| 92012 Ophthalmological E&M | Office | 119 | 76 | $65.17 | $7,755 |
| 83861 Clinical Chemistry | Office | 104 | 41 | $22.03 | $2,291 |
| 92083 Vision, Hearing, and Speech Services | Office | 73 | 61 | $44.38 | $3,240 |
| 92004 Ophthalmological E&M | Office | 56 | 56 | $92.90 | $5,202 |
| 92133 Computerized Ophthalmic Imaging | Office | 54 | 52 | $27.17 | $1,467 |
| 99214 Office E&M - Established | Office | 51 | 39 | $104.42 | $5,326 |
| 92002 Ophthalmological E&M | Office | 41 | 41 | $58.97 | $2,418 |
| 92134 Computerized Ophthalmic Imaging | Office | 35 | 34 | $28.53 | $998 |
| 99213 Office E&M - Established | Office | 19 | 18 | $68.75 | $1,306 |
By year: 2022 $61K for 908 services; 2023 $57K for 883 services; 2024 $62K for 1,075 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83861 Clinical Chemistry | 104 | 41 | $22.03 | $2,291 |
Medicare prescription drug claims, 2024
In 2024, the drug Tamscot Yap prescribed most often to Medicare patients was Tobramycin-Dexamethasone (Tobramycin/Dexamethasone), with 159 prescriptions and refills. In total Tamscot Yap wrote 972 Medicare prescriptions that cost $234K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tobramycin-Dexamethasone Tobramycin/Dexamethasone | 159 | 161 | 141 | $5,051 |
| Latanoprost Generic | 149 | 412 | 56 | $1,417 |
| Erythromycin Erythromycin Base | 89 | 89 | 52 | $895 |
| Restasis Cyclosporine | 51 | 99 | 23 | $62K |
| Prednisolone Acetate Generic | 51 | 56 | 38 | $1,533 |
| Valacyclovir Valacyclovir Hcl | 37 | 40 | 16 | $1,779 |
| Doxycycline Hyclate Generic | 37 | 40 | 37 | $539 |
| Cyclosporine Generic | 31 | 85 | 14 | $17K |
| Lumigan Bimatoprost | 30 | 47 | Under 11 | $13K |
| Moxifloxacin Moxifloxacin Hcl | 30 | 30 | 24 | $662 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 27 | 59 | Under 11 | $392 |
| Xiidra Lifitegrast | 26 | 64 | 12 | $44K |
| Tyrvaya Varenicline Tartrate | 20 | 30 | Under 11 | $20K |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 19 | 19 | 19 | $93.9 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 18 | 18 | 15 | $180 |
Brand drugs: 356 claims; generic drugs: 616 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tamscot Yap $612 ($612 in general payments such as food, travel and fees) from 10 companies. The largest payer was Alcon Vision LLC with $114.
| Company | Payments | Amount |
|---|---|---|
| Alcon Vision LLC ALC | 5 | $114 |
| Harrow Eye, LLC | 4 | $101 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 3 | $84.5 |
| Bausch & Lomb Americas Inc. BLCO | 4 | $82.58 |
| Dompe US, Inc. | 3 | $70.56 |
| Tarsus Pharmaceuticals, Inc. TARS | 3 | $50.05 |
| Genzyme Corporation SNY | 1 | $48.08 |
| Thea Pharma Inc. | 1 | $24.29 |
| Oyster Point Pharma, Inc. | 1 | $23.19 |
| Abbvie Inc. ABBV | 1 | $14.1 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.